Sirenas applies computational metabolomics to marine natural product chemistry, discovering new therapeutic and health product candidates from oceanic biodiversity. Leveraging its ATLANTIS™ platform, the company translates marine microbiome insights into drug discovery pipelines, recently supported by a $1.68 M grant from the Bill & Melinda Gates Foundation to accelerate its technology.
Funding
$1.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug discovery relies heavily on terrestrial sources and synthetic chemistry, which can limit the chemical diversity available for novel therapeutics. Accessing and characterizing bioactive compounds from marine ecosystems is challenging due to the complexity of samples, the need for sustainable collection, and the difficulty of linking chemistry to biological activity.
Solution
Sirenas applies computational metabolomics through its proprietary ATLANTIS™ platform to rapidly profile the chemical space of marine organisms. By integrating high‑throughput extraction, advanced mass spectrometry, and machine‑learning algorithms, the platform maps previously uncharted marine metabolites to potential health applications. This approach accelerates the identification of new chemical classes for pharmaceutical and nutraceutical development while maintaining sustainable and ethical sourcing practices. The resulting data repository connects marine chemistry with biomedical relevance, enabling partners to advance candidates through preclinical pipelines more efficiently.
Target Audience
Primary customers are pharmaceutical and nutraceutical companies seeking novel marine‑derived bioactive compounds, as well as research institutions focused on natural product chemistry and drug discovery.
Features
- Large, ethically sourced library of marine organisms and plants collected in partnership with local communities
- High‑resolution mass spectrometry coupled with AI‑driven metabolomic analysis to decode complex natural product mixtures
- ATLANTIS™ computational engine that predicts bioactivity and prioritizes compounds for drug development
- Integrated workflow that links chemical discovery to downstream pharmacology and formulation efforts
- Sustainable extraction methods that minimize environmental impact while preserving sample integrity